Probenecid

Probenecid
Clinical data
Trade names	Probalan
AHFS/Drugs.com	Monograph
MedlinePlus	a682395
Routes of; administration	By mouth
ATC code	M04AB01 (WHO) ;
Legal status
Legal status	In general: ℞ (Prescription only);
Pharmacokinetic data
Protein binding	75-95%
Elimination half-life	2-6 hours (dose: 0.5-1 g)
Excretion	kidney (77-88%)
Identifiers
	IUPAC name 4-(dipropylsulfamoyl)benzoic acid;
CAS Number	57-66-9 ;
PubChem CID	4911;
IUPHAR/BPS	4357;
DrugBank	DB01032 ;
ChemSpider	4742 ;
UNII	PO572Z7917;
KEGG	D00475 ;
ChEMBL	ChEMBL897 ;
CompTox Dashboard (EPA)	DTXSID9021188 ;
ECHA InfoCard	100.000.313
Chemical and physical data
Formula	C13H19NO4S
Molar mass	285.36 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=S(=O)(N(CCC)CCC)c1ccc(C(=O)O)cc1;
	InChI InChI=1S/C13H19NO4S/c1-3-9-14(10-4-2)19(17,18)12-7-5-11(6-8-12)13(15)16/h5-8H,3-4,9-10H2,1-2H3,(H,15,16) ; Key:DBABZHXKTCFAPX-UHFFFAOYSA-N ;
	(verify)

Probenecid, also sold under the brand name Probalan, is a medication that increases uric acid excretion in the urine. It is primarily used in treating gout and hyperuricemia.

Probenecid was developed as an alternative to caronamide^[1] to competitively inhibit renal excretion of some drugs, thereby increasing their plasma concentration and prolonging their effects.

^ Mason RM (June 1954). "Studies on the effect of probenecid (benemid) in gout". Annals of the Rheumatic Diseases. 13 (2): 120–130. doi:10.1136/ard.13.2.120. PMC 1030399. PMID 13171805.

[pmid13171805-1] Mason RM (June 1954). "Studies on the effect of probenecid (benemid) in gout". Annals of the Rheumatic Diseases. 13 (2): 120–130. doi:10.1136/ard.13.2.120. PMC 1030399. PMID 13171805.

[1]